MedTrace Logo

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

NCT04983940 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2023-12-14

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to evaluate patient satisfaction with an oral testosterone agent, Jatenzo, compared to other forms of testosterone therapy.

Conditions

  • Testosterone Deficiency

Interventions

DRUG

Jatenzo

237 mg soft gel capsule taken twice a day by mouth with food.

Sponsors & Collaborators

  • Clarus Therapeutics, Inc.

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Ranjith Ramasamy, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-18
Primary Completion
2023-04-06
Completion
2023-04-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04983940 on ClinicalTrials.gov